Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
27 avr. 2021 01h00 HE
|
Novartis Pharma AG
Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb auf...
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
27 avr. 2021 01h00 HE
|
Novartis Pharma AG
Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with...
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
30 mars 2021 01h15 HE
|
Novartis Pharma AG
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad...
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
23 mars 2021 02h15 HE
|
Novartis Pharma AG
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive...
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
15 mars 2021 06h00 HE
|
Novartis Pharma AG
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,...
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
09 mars 2021 01h00 HE
|
Novartis Pharma AG
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
02 mars 2021 09h26 HE
|
Novartis International AG
Les actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-flow...
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
02 mars 2021 09h26 HE
|
Novartis International AG
Die Aktionäre bewilligen die 24. Dividendenerhöhung in Folge. Für 2020 wird die Dividende auf CHF 3.00 (+1,7%) je Aktie erhöht, was einer Rendite von 3,8%1 und einem Anteil des freien...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
02 mars 2021 09h26 HE
|
Novartis International AG
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg...
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
16 févr. 2021 13h23 HE
|
Novartis International AG
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction...